Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Adds Two Breast-Cancer Treatment Approvals in One Day
The FDA listed June 24 approvals for sacituzumab govitecan in triple-negative breast cancer and palbociclib maintenance therapy in HR-positive, HER2-positive metastatic breast cancer.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA oncology approval tracker added two breast-cancer decisions dated 24 June 2026, making the day a notable one for oncology treatment options.
One decision approved sacituzumab govitecan-hziy, sold as Trodelvy, for two indications in adults with triple-negative breast cancer. A second approved palbociclib, sold as Ibrance, with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment.
Pfizer said the palbociclib decision was based on the Phase 3 PATINA trial and described the approval as extending CDK4/6 inhibition into a broader HER2-positive metastatic setting.
Sourcing note: The FDA tracker establishes the approval decisions and dates. Company statements add trial framing and commercial interpretation, which should be read as sponsor context rather than independent clinical guidance.
Why It Matters
Oncology progress is often incremental, but new labels can change sequencing, maintenance strategy and payer discussions quickly, especially in breast-cancer subtypes where biomarker-defined treatment paths are already complex.
What to Watch
Watch clinical uptake, real-world tolerability, reimbursement decisions and how oncologists position these options against existing antibody-drug conjugate and CDK4/6 inhibitor regimens.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDABreast CancerOncologyTriple-Negative Breast CancerMetastatic Breast Cancer